Genevieve Konopka

Genevieve Konopka

Auto-generated profile, based on publicly available information

Genevieve Konopka

Department of Neuroscience, University of Texas Southwestern Medical Center, Dallas, USA

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 October 2008 in Nature Neuroscience
Verified
Journal Article
Closed access
PDF file
MOMichael C Oldham
Michael C Oldham
GKGenevieve Konopka
Genevieve Konopka
KIKazuya Iwamoto
Kazuya Iwamoto
PLPeter Langfelder
Peter Langfelder
TKTadafumi Kato
Tadafumi Kato
DGDaniel H Geschwind
Daniel H Geschwind

17 September 2001 in Nature Cell Biology
Verified
Journal Article
Closed access
PDF file
LPLuigi Puglielli
Luigi Puglielli
GKGenevieve Konopka
Genevieve Konopka
EPEunju Pack-Chung
Eunju Pack-Chung
LILaura A. MacKenzie Ingano
Laura A. MacKenzie Ingano
OBOksana Berezovska
Oksana Berezovska
DKDora M. Kovacs
Dora M. Kovacs

1 August 2019 in Current Opinion in Biotechnology
Verified
Journal Article
Closed access
AKAshwinikumar Kulkarni
Ashwinikumar Kulkarni
AAAshley G. Anderson
Ashley G. Anderson
DMDevin P. Merullo
Devin P. Merullo
GKGenevieve Konopka
Genevieve Konopka

12 November 2009 in Nature
Verified
Journal Article
Open access
PDF file
GKGenevieve Konopka
Genevieve Konopka
JBJamee M. Bomar
Jamee M. Bomar
KWKellen Winden
Kellen Winden
GCGiovanni Coppola
Giovanni Coppola
ZJZophonías Oddur Jónsson
Zophonías Oddur Jónsson
DGDaniel H. Geschwind
Daniel H. Geschwind
The transcription factor FOXP2 is the only gene so far to have been implicated in human speech, yet it differs very little from the chimpanzee equivalent. New experiments reveal differences between the activation of downstream transcriptional targets of FOXP2 in humans and chimpanzees arising from the two amino acid differences between the two forms of FOXP2. The different gene network interactions influenced by each version of FOXP2 are also reflected in the non-overlapping brain expression patterns exhibited by chimps and humans. These data provide support for the idea that evolutionary changes to FOXP2 in the human lineage have direct consequences for human brain development and disease in the central nervous system and may have a critical role in the development of language circuitry in humans. The transcription factor FOXP2 is the only gene implicated in human speech, and yet it differs very little from the chimpanzee orthologue. Here, the two amino acids specific to humans are shown to alter FOXP2 function in vitro by conferring differential transcriptional regulation, and these observations are extended in vivo to human and chimpanzee brain. Together, these data identify transcriptional targets that may serve critical functions in language development. The signalling pathways controlling both the evolution and development of language in the human brain remain unknown. So far, the transcription factor FOXP2 (forkhead box P2) is the only gene implicated in Mendelian forms of human speech and language dysfunction1,2,3. It has been proposed that the amino acid composition in the human variant of FOXP2 has undergone accelerated evolution, and this two-amino-acid change occurred around the time of language emergence in humans4,5. However, this remains controversial, and whether the acquisition of these amino acids in human FOXP2 has any functional consequence in human neurons remains untested. Here we demonstrate that these two human-specific amino acids alter FOXP2 function by conferring differential transcriptional regulation in vitro. We extend these observations in vivo to human and chimpanzee brain, and use network analysis to identify novel relationships among the differentially expressed genes. These data provide experimental support for the functional relevance of changes in FOXP2 that occur on the human lineage, highlighting specific pathways with direct consequences for human brain development and disease in the central nervous system (CNS). Because FOXP2 has an important role in speech and language in humans, the identified targets may have a critical function in the development and evolution of language circuitry in humans.

1 August 2012 in Neuron
Verified
Journal Article
Closed access
GKGenevieve Konopka
Genevieve Konopka
TFTara Friedrich
Tara Friedrich
JDJeremy Davis-Turak
Jeremy Davis-Turak
KWKellen Winden
Kellen Winden
MOMichael C. Oldham
Michael C. Oldham
DGDaniel H. Geschwind
Daniel H. Geschwind

7 February 2008 in Genes & Development
Verified
Journal Article
Closed access
PDF file
NINúria de la Iglesia
Núria de la Iglesia
GKGenevieve Konopka
Genevieve Konopka
Sidharth PuramSidharth Puram
Sidharth Puram
JCJennifer A. Chan
Jennifer A. Chan
RBRobert M. Bachoo
Robert M. Bachoo
ABAzad Bonni
Azad Bonni
Activation of the transcription factor STAT3 is thought to potently promote oncogenesis in a variety of tissues, leading to intense efforts to develop STAT3 inhibitors for many tumors, including the highly malignant brain tumor glioblastoma. However, the function of STAT3 in glioblastoma pathogenesis has remained unknown. Here, we report that STAT3 plays a pro-oncogenic or tumor-suppressive role depending on the mutational profile of the tumor. Deficiency of the tumor suppressor PTEN triggers a cascade that inhibits STAT3 signaling in murine astrocytes and human glioblastoma tumors. Specifically, we forge a direct link between the PTEN–Akt–FOXO axis and the leukemia inhibitory factor receptor β (LIFRβ)–STAT3 signaling pathway. Accordingly, PTEN knockdown induces efficient malignant transformation of astrocytes upon knockout of the STAT3 gene. Remarkably, in contrast to the tumor-suppressive function of STAT3 in the PTEN pathway, STAT3 forms a complex with the oncoprotein epidermal growth factor receptor type III variant (EGFRvIII) in the nucleus and thereby mediates EGFRvIII-induced glial transformation. These findings indicate that STAT3 plays opposing roles in glial transformation depending on the genetic background of the tumor, providing the rationale for tailored therapeutic intervention in glioblastoma.